H.C. Wainwright raised the firm’s price target on Editas Medicine (EDIT) to $5 from $3 and keeps a Buy rating on the shares following the Q2 report. The firm cites a more favorable expense trajectory for the target increase.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT: